Inhibitors of hepatitis C virus NS3 protease

Details Inhibitors of hepatitis C virus NS3 protease Inhibitors of hepatitis C virus NS3 protease

2007-04-17

2007-04-17

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S143000, C544S295000, C544S357000, C544S373000, C546S200000, C546S277100, C548S181000, C548S235000, C548S537000, C549S059000, C549S473000

Reexamination Certificate

active

11065572

ABSTRACT:
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

REFERENCES:
patent: 5712145 (1998-01-01), Houghton et al.
patent: 6608027 (2003-08-01), Tsantrizos et al.
patent: 0 639 585 (1995-02-01), None
patent: 0 381 216 (1995-12-01), None
patent: WO 89/04669 (1989-06-01), None
patent: WO 98/14181 (1998-04-01), None
patent: WO 98/17679 (1998-04-01), None
patent: WO 98/22496 (1998-05-01), None
patent: WO 99/07734 (1999-02-01), None
patent: WO 00/09543 (2000-02-01), None
patent: WO 00/09558 (2000-02-01), None
patent: WO 00/59929 (2000-10-01), None
patent: WO 01/74768 (2001-10-01), None
patent: WO 01/77113 (2001-10-01), None
patent: WO 01/81325 (2001-11-01), None
patent: WO 02/08187 (2002-01-01), None
patent: WO 02/08198 (2002-01-01), None
patent: WO 02/08244 (2002-01-01), None
patent: WO 02/08251 (2002-01-01), None
patent: WO 02/08256 (2002-01-01), None
patent: WO 02/18369 (2002-03-01), None
patent: WO 02/48172 (2002-06-01), None
patent: WO 03/062265 (2003-07-01), None
patent: WO 2003062265 (2003-07-01), None
patent: WO 2004/033425 (2004-04-01), None
U.S. App. No. 10/052,386, filed Jan. 18, 2002.
Berenguer, Marina, et al., “Hepatitis B and C . . . , ” Proceedings of the Association of American Physicians 110(2):98-112 (1998).
Chen, Shu-Hui, et al., “Synthesis and Evaluation . . . , ” Bioorganic & Medicinal Chemistry Letters 13:3531-36 (2003).
Dimasi, Nazzareno, et al., “Characterization of Engineered . . . , ” Journal of Virology 71(10):7461-69 (Oct. 1997).
Elzouki, Abdul-Nasser, et al., “Serine protease inhibitors . . . , ” Journal of Hepatology 27:42-48 (1997).
Failla, Cristina Maria, et al., “Redesigning the substrate . . . , ” Folding & Design 1:35-42 (Jan. 10, 1998).
Han, Wei, et al., “alpha-Ketoamides, alpha Ketoesters . . . , ” Bioorganic & Medicinal Chemistry Letters 10:711-13 (2000).
Hoofnagle, Jay H., et al., “The Treatment of Chronic . . . ,” Drug Therapy 336(5):347-56 (Jan. 30, 1997).
Ingallinella, Paola, et al., “Potent Peptide Inhibitors . . . ,” Biochemistry 37:8906-14 (1998).
Kolykhalov, Alexander A., et al., “Specificity of the Hepatitis C . . . ,” Journal of Virology 68(11):7525-7533 (1994).
Komoda, Yasumasa, et al., “Substrate Requirements of . . . ,” Journal of Virology 68(11):7351-7357 (1994).
Lamar, Jason, et al., “Novel P4 truncated . . . ,” Bioorganic & Medicinal Chemistry Letters 14:263-266 (2004).
Landro, James A., et al., “Mechanistic Role of an . . . ,” Biochemistry 36:9340-8 (19997).
Llinas-Brunet, Montse, et al., “Peptide-Based Inhibitors . . . ,” Bioorganic & Medicinal Chemistry Letters 8:1713-8 (1998).
Marchetti, Antonella, et al., “Synthesis of Two Novel . . . ,” Synlett S1:1000-2 (1999).
Martin, F., et al., “Affinity selection of . . . ,” Protein Engineering 10(5):607-14 (1997).
Martin, Franck, et al., “Design of Selective . . . ,” Biochemistry 37:11459-68 (1998).
Pizzi, Elisabetta, et al., “Molecular model of . . . ,” Proc. Natl. Acad. Sci. 91:888-92 (Feb. 1994).
BioWorld Today 9(217): (Nov. 10, 1998).
PCT International Search Report dated Jul. 29, 2005 for corresponding PCT Application No. PCT/US2005/006502.

Affiliated with

Also associated with

Rating

Inhibitors of hepatitis C virus NS3 protease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of hepatitis C virus NS3 protease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of hepatitis C virus NS3 protease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3756793